Form 4: Harvard Bioscience CEO James W. Green Acquires 10,000 Shares of Common Stock
SEC Form 4 Filing
James W. Green, CEO of Harvard Bioscience, recently purchased 10,000 shares of the company's common stock at a price of $2.91 per share.
Summary
- On June 13, 2024, James W. Green, the CEO of Harvard Bioscience, acquired 10,000 shares of common stock.
- The purchase price was $2.91 per share.
- Following the transaction, Green directly owns 3,111,091 shares of Harvard Bioscience common stock.
- This total includes 235,427 RSUs vesting in two equal installments on December 29, 2024 and 2025.
- It also includes 52,346 RSUs vesting on December 29, 2024, and 214,797 RSUs vesting in three equal installments on March 19, 2025, 2026 and 2027.
- Additionally, it includes 699,772 RSUs with performance-based vesting conditions and 1,908,749 shares of common stock beneficially owned by the Reporting Person.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's performance.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs indicate future equity compensation.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the size of the purchase relative to the executive's overall holdings and the company's market capitalization.
Comparison to Industry Standards
- Comparing insider trading activity at Harvard Bioscience to similar companies in the life sciences or biotechnology sectors could provide context.
- For example, companies like Thermo Fisher Scientific or Danaher Corporation could be used as benchmarks to assess the significance of this transaction.
- Analyzing the frequency and size of insider buys and sells in these comparable companies can help determine whether this transaction is typical or noteworthy.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal.
- Employees may see it as a sign of leadership's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: James W. Green purchased 10,000 shares of HBIO. |
| 06/14/2024 | Date of filing: Form 4 filing date. |
| 12/29/2024 | Vesting date for 235,427 RSUs (first installment) and 52,346 RSUs. |
| 12/29/2025 | Vesting date for 235,427 RSUs (second installment). |
| 03/19/2025 | Vesting date for 214,797 RSUs (first installment). |
| 03/19/2026 | Vesting date for 214,797 RSUs (second installment). |
| 03/19/2027 | Vesting date for 214,797 RSUs (third installment). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.